Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Trial Profile

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALRN 6924 (Primary) ; Palbociclib (Primary)
  • Indications Colorectal cancer; Haematological malignancies; Liposarcoma; Merkel cell carcinoma; Peripheral T-cell lymphoma; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms All-comers
  • Sponsors Aileron Therapeutics
  • Most Recent Events

    • 28 Oct 2019 According to an Aileron Therapeutics media release, as of the data cutoff date of September 2, 2019, the trial had enrolled 26 patients.The vast majority of patients enrolled thus far are sarcoma patients, including 20 with liposarcoma.
    • 28 Sep 2019 According to an Aileron Therapeutics media release, interim data were presented at the 2019 Congress of the European Society for Medical Oncology (ESMO).
    • 28 Sep 2019 Interim results presented in an Aileron Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top